NARACHI MICHAEL 4

What Happened
Michael Narachi, a director of Ultragenyx Pharmaceutical Inc. (RARE), received equity awards reported on 2026-05-14: 7,751 restricted stock units (RSUs) and a derivative award/option covering 14,058 shares. Both awards show an acquisition price of $0.00, so no cash was paid. The filing shows no immediate sale — these are awards that vest in the future rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-05-14; Form 4 filed 2026-05-18 (filed within the typical 2-business-day reporting window).
• Awards: 7,751 RSUs (grant) and 14,058-share derivative/option (grant) at $0.00 (total cash paid = $0).
• Vesting: Both awards vest in full on the earlier of the Company’s next Annual Meeting of Stockholders or May 14, 2027 (Footnotes F1–F2).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No 10b5-1, tax-withholding, or immediate cashless-sale indicators noted in the provided data.

Context
RSUs and option/derivative grants are compensation awards that convert to stock only after vesting; they do not indicate an immediate market purchase or sale. For retail investors, such grants are routine director compensation and do not by themselves signal buying or selling intent.